Key Findings
Lonza, a leading global contract development and manufacturing organization (CDMO), has announced plans for a significant expansion of its commercial-scale antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp site in Switzerland. This strategic investment is aimed at establishing new commercial-scale capabilities for highly complex and potent active pharmaceutical ingredients (APIs) and ADC payload-linkers, providing robust support for the rapidly expanding oncology pipeline of ADCs.
Technical / Clinical Details
ADCs represent a next-generation class of anti-cancer agents, combining a monoclonal antibody that targets specific cancer cells with a highly potent cytotoxic payload (drug) via a chemically stable linker. The manufacturing process for ADCs is exceptionally complex, particularly the synthesis of the payload (often a highly potent API, or HPAPI) and the development and manufacturing of the linker that attaches it to the antibody. These steps require specialized expertise and stringent containment facilities. Lonza’s expansion at its Visp site involves the integration of state-of-the-art equipment to handle these intricate processes and meet large-scale manufacturing demands. This initiative will facilitate a seamless transition from R&D to commercial production, contributing to the stable supply of ADCs.
Background & Context
The ADC market has experienced rapid growth in recent years, driven by a series of breakthroughs in oncology. As numerous pharmaceutical companies bolster their ADC pipelines, the demand for high-quality contract manufacturing of ADC components (payloads, linkers) has dramatically increased. CDMOs play a crucial role in mitigating R&D risks and accelerating time-to-market for pharmaceutical companies by providing the necessary expertise and facilities for these advanced manufacturing needs. Lonza’s current investment addresses the global shortage in ADC manufacturing capacity and strengthens its competitive position in the market.
Strategic Significance & Outlook
Lonza’s manufacturing capacity expansion signifies a substantial commitment to the burgeoning ADC market. This will enable Lonza to offer more clients flexible and scalable solutions for ADC development and manufacturing. Moving forward, the development of new ADCs for a wider range of cancer types is expected to accelerate, bringing new hope to patients resistant to existing treatments or those seeking therapies with fewer side effects. Investments by leading CDMOs like Lonza are indispensable for fostering further innovation in ADC technology and ensuring the diversification and stable supply of medicines that ultimately reach patients.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments